September 23, 2019
FDA: Class I recall of Allergan Natrelle Biocell textured breast implants
Editor's Note
The Food & Drug Administration (FDA) on September 12 designated the recall by Allergan of its Natrelle Biocell textured breast implants as Class I, the most serious.
The recall was initiated because of a six times higher rate of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a cancer of the immune system, which has been associated with these implants.
Distribution dates are September 14, 2014, to July 24, 2019.
Free Daily News
- Catheter sterility concerns prompt Class 1 FDA recall for surgery trays
- Large amounts of personal data possibly stolen in Change Healthcare cyberattack
- AI model helps predict patient decline, drive collaborative care
- One patient’s recovery highlights benefits of outpatient endoscopic spine surgery
- Getting ready for the OAS CAHPS Survey 2025 requirement
- Contribute to perioperative education with the 2024 OR Manager Salary/Career Survey
- Supply chain stability improves, but threats remain
- Private equity healthcare ownership draws new scrutiny
- Share your expertise! Topics, speakers sought for 2025 ORBMC
- FDA approves imaging drug for detecting cancer after lumpectomy
© Access Intelligence, LLC. All rights reserved. | Privacy Policy | Diversity, Equity, Inclusion & Belonging